Compounds with real evidence

Only what has genuine backing.

Level I · Multiple meta-analyses

Ω3

Liao (2019, 26 RCTs): SMD=−0.28 in depression. Greater efficacy as adjunct with EPA≥60%.

1–2 g/day EPA · EPA≥60% ratio

⚠ Anticoagulants: bleeding risk at high doses.

Level I · Meta-analysis

NMDA antagonist and HPA modulator. Moabedi (2023, 7 RCTs): SMD=−0.92 in MDD.

200–400 mg/day · glycinate or citrate preferred

⚠ Renal impairment: contraindicated.

Level I

D₃

Ghaemi (2024, 31 RCTs): per 1,000 IU/day SMD=−0.32; active symptoms SMD=−0.57.

Deficiency correction · typically 1,000–4,000 IU/day

⚠ Hypercalcaemia at very high doses.

Level II · Reactive HPA

Blunts reactive ACTH release at pituitary. Improves glucocorticoid receptor sensitivity. Synergistic with omega-3.

200–400 mg/day · effects in days–2 weeks

⚠ Caution with anticoagulants at high doses.

Level II · Chronic HPA

Ash

Recalibrates chronic HPA setpoint. Chandrasekhar (2012): 27.9% cortisol reduction (p<0.0001). Increases HRV.

300–600 mg/day KSM-66 extract

⚠ Autoimmune thyroid · pregnancy · sedatives · rare hepatotoxicity.

With clinical judgement, not an internet article.

We assess what makes sense in your specific case.

No rush. No obligation. We talk about what brought you here.